Infectious Diseases studies

Our researchers address the unique challenges of prevention, treatment, and outcomes of various infectious diseases. We conduct a number of clinical trials, vaccine-related studies, and examine a broad range of topics including hospital infections, antibiotic stewardship, environmental pathogens, influenza, hepatitis C. Studies have addressed the safety and efficacy of new hepatitis treatments, safety and effectiveness of the shingles vaccine; the safety of the quadrivalent human papillomavirus vaccine; testing and vaccination for hepatitis B, and uptake of childhood vaccinations.

A Retrospective Natural History Study of Coccifioidmycosis in California

Knowledge gaps exist regarding disease risk factors, presenting signs and symptoms, diagnostic approaches, and treatment for coccidiodomycosis infection. This study evaluates a large cohort of patients with community-acquired pneumonia in Southern California to assess cocci testing practices; additionally we evaluate a large cohort of patients diagnosed with cocci during 2011 to assess the natural history of infection.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2014 - 2017

Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experiment

This study will allow us to comprehensively evaluate the casual link between food animal use of antibiotics, food product contamination, and human disease. These findings will inform future policy interventions towards a potentially modifiable source of AMR to reduce the burden on human populations nationally and globally.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

National Institutes of Health (NIH)

Funding Years:

2017 - 2022

Do inpatient antimicrobial stewardship programs help us in the battle against antimicrobial resistance?

We propose to conduct a comprehensive analysis of the impact of ASPs on relevant clinical outcomes in a large integrated health care system. Specifically, we will evaluate the changes in consumption of targeted ASP drugs pre- and post-ASP and the changes in inpatient infection rates with clinically important drug-resistant organisms (DROs) pre- and post-ASP.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

National Institutes of Health (NIH)

Funding Years:

2017 - 2019

Economic, Epidemiologic and Clinical Burden Associated with Neutropenia and Febrile Neutropenia in Three Cancers

The primary objective of this study is to estimate the resource utilization and direct medical expenditure associated with neutropenia and febrile neutropenia, in Non-Hodgkin’s Lymphoma, Breast cancer and Lung cancer patients. The secondary objective is to determine the trend of incidence of neutropenia with and without fever in Non-Hodgkin’s Lymphoma, Breast cancer and Lung cancer. The study will also describe management patterns and evaluate trend of management patterns for febrile neutropenia. Lastly, we will also estimate the febrile neutropenia specific mortality rate in hospitalized patients by cancer type.

Principal Investigator:

Aniket A. Kawatkar, PhD, MS

Funding Source:

Amgen, Inc.

Funding Years:

2011 - 2015

GWU/Wellcome 1 Feasibility

To collect preliminary data to support the larger Wellcome grant.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

The George Washington University

Funding Years:

2018 - 2019

HIV Status and Incidence and Outcomes of Heart Failure

The overall goal of this study is to identify optimal treatment strategies to reduce the impact of cardiovascular disease complications in HIV-infected patients, focusing on the understudied diagnosis of heart failure

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

National Heart, Lung, and Blood Institute (NHLBI)

Funding Years:

2016

Identification of risk factors for resistant Pseudomonas aeruginosa infections with or without ESBL among hospitalized patients and developments and validation of a risk predictive tool

This study aims to develop a clinical risk prediction tool for antibiotic resistant Pseudomonas infections among inpatients.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2016 - 2019

Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection

Studies evaluating the role of hepatitis C viral (HCV) infection on the progression of CKD are few and conflicting. Therefore, we evaluated the association of untreated HCV on kidney function decline in patients with stage 3-5 CKD.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2014 - 2017

Learning from California Senate bill 27: a natural experiment

This study complements an ongoing R01 study to provide more compelling evidence regarding the impact of SB27 by examining all major meat types (chicken, turkey, pork and beef) that may be impacted by the bill. Likewise, we include collection of the frank foodborne pathogens, Salmonella and Campylobacter, to provide additional insights into the potential effectiveness of this policy intervention.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Wellcome Trust

Funding Years:

2018 - 2022

Prenatal Antibiotic Use and Body Weight in Children

The goal of this study is to examine the potential relationship between antibiotic use during pregnancy and pediatric weight problems.

Principal Investigator:

Corinna Koebnick, PhD, MSc

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2017 - 2019

The Effects of Influenza Vaccination on The Rate of Serious Health Effects

The objective of this study is to document the influenza vaccine's effect on reducing influenza-related morbidity and mortality among individuals at broader age ranges.

Principal Investigator:

Hung Fu Tseng, PhD, MPH

Funding Source:

National Institute on Aging (NIA)

Funding Years:

2014

Vaccine Safety Datalink Project-CDC

VSD is a multi-site study of vaccine safety in a network of managed care organizations from across the US. The VSD project allows for planned immunization safety studies as well as timely investigations of hypotheses that arise from review of medical literature, reports to the Vaccine Adverse Event Reporting System (VAERS), changes in immunization schedules, or the introduction of new vaccines.

Principal Investigator:

Steven J. Jacobsen, MD, PhD

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2012 - 2022